• Recruiting

NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory

Updated: May 26

(LUMMICAR STUDY 2)

ct053

NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)


A phase 1b, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.


Sponsor

CARsgen Therapeutics Co., Ltd


Multiple locations International study

 

ClinicalTrials.gov Identifier: NCT03915184


Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)


First Posted : April 16, 2019


Click here for details on Clinicaltrials.gov

 

Anti-BCMA-targeting CAR-T Cells (Code C176023)

Anti-BCMA-targeting CAR-T Cells (Code C176023)

CART - BCMA : National Cancer Institute


Genetic: CAR-BCMA T cells

autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T cells CT053

BCMA Car-T (CT053)

CAR-BCMA T cells CT053

Biological: CT053

CT053


Drug: Fludarabine

Drug: Cyclophosphamide

 

Related Study:

(LUMMICAR STUDY 1)

NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)


CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting


Poster #2821: Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma


Poster #1751: Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors

 

704.Cellular Immunotherapies: Clinical| November 5, 2021

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

https://ashpublications.org/blood/article/138/Supplement%201/1751/480716/Integrated-Analysis-of-B-Cell-Maturation-Antigen



704.Cellular Immunotherapies: Clinical| November 5, 2021

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

https://ashpublications.org/blood/article/138/Supplement%201/2821/481343/Sustainable-Efficacy-and-Safety-Results-from

 

133 Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data

Hematology Disease Topics & Pathways:

multiple myeloma, Biological, Diseases, Therapies, CAR-Ts, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant

Saturday, December 5, 2020: 10:30 AM

https://ash.confex.com/ash/2020/webprogram/Paper139802.html

 

- Florida: Moffitt Cancer Center Tampa

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- Texas: The University of Texas MD Anderson Cancer Center Houston

- Texas: UT Southwestern Medical Center Dallas

- Wisconsin: Medical College Of Wisconsin Milwaukee

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Florida

United States, Massachusetts

United States, Michigan

United States, Michigan

United States, New York

United States, Tennessee

United States, Texas

United States, Utah

United States, Wisconsin

Canada, Ontario









Posts Archive